Investigational drug · Phase 2
PL8177
Also called: Active study medication
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "PL8177"
First trial start
2022
Sep 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PL8177", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ulcerative Colitis
- Ulcerative Colitis Acute
- Ulcerative
- Ulcerative Colitis Flare
Approved drugs for the same conditions: Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "PL8177" as an intervention, largest first.
- Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)Active, not recruiting
Palatin Technologies, IncIndustry
NCT05466890 · 16 participants (planned) · Start Sep 15, 2022 · Primary completion Feb 10, 2025
Drug: PL8177 Placebo; PL8177 · For: Ulcerative Colitis; Ulcerative Colitis Acute; Ulcerative and 1 more
Sites: Tucson, Arizona; Lancaster, California; Tarzana, California · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans.
Dodd J, Jordan R, Makhlina M, et al. · Front Immunol 2023
- Pro-resolving and anti-arthritic properties of the MC1 selective agonist PL8177.
Garrido-Mesa J, Thomas BL, Dodd J, et al. · Front Immunol 2022
- Melanocortin receptor agonists suppress experimental autoimmune uveitis.
Ng TF, Dawit K, Taylor AW · Exp Eye Res 2022
- Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants.
Peters EN, Mosesova I, MacNair L, et al. · J Anal Toxicol 2022
- Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration.
Dodd J, Jordan R, Makhlina M, et al. · Drugs R D 2021
- Probing the Role of Melanocortin Type 1 Receptor Agonists in Diverse Immunological Diseases.
Spana C, Taylor AW, Yee DG, et al. · Front Pharmacol 2018
Also in development for Ulcerative Colitis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- ABX464ObefazimodPhase 35 trials
Abivax S.A. · Ulcerative Colitis, Moderately to Severely Active Crohn Disease
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.